Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

September 30, 2015

Conditions
Hepatitis C Virus
Interventions
DRUG

ABT-450/r/ABT-267

Tablet; ABT-450 coformulated with ritonavir and ABT-267

DRUG

Ribavirin

Capsule

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY